Vectura and UCB to collaborate on severe inflammatory disease

30 September 2013

UK developer of Inhaled therapies Vectura (LSE: VEC) and Belgian drugmaker UCB (Euronext Brussels; UCB) have entered into a collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory respiratory disease. Financial terms of the agreement have not been disclosed.

The collaboration aims to leverage Vectura’s expertise in the pharmaceutical and clinical/regulatory development of inhaled therapeutics with UCB’s biologics and immunology assets. It will focus on bringing to clinical proof-of-concept an unidentified UCB-generated biological therapy targeting a key molecule in the immune system.

Joint management of the program

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK